A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain ...

The PDUFA dates have been pushed for sotorasib and obeticholic acid for metastatic colorectal cancer and primary biliary ...

Pharmacologic strategies may be able to prevent abnormal uterine bleeding in patients undergoing stem cell transplant.

Treatment effectiveness can have different meanings to patients,” a physician assistant said when discussing therapy for high ...

A poll of experts revealed that few are utilizing talquetamab for patients with pretreated relapsed/refractory myeloma.

Extensive-stage (stage IV) SCLC, on the other hand, is a disease that has spread outside the bounds of 1 radiation field, and ...

After a patient with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer experiences disease progression ...

Providers should consider lifestyle preferences and other conditions/comorbidities before deciding between bispecific antibodies or CAR T-cell therapy in myeloma. Lifestyle preferences and baseline ...

Inavolisib plus palbociclib and fulvestrant was approved for the treatment of PIK3CA-mutant, HR-positive, HER2-negative locally advanced or metastatic breast cancer. The FDA approved inavolisib ...

The FDA approved zolbetuximab-clzb (Vyloy) plus fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with locally advanced unresectable or metastatic HER2-negative ...